Truist raised the firm’s price target on Collegium Pharmaceutical (COLL) to $55 from $47 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical Closes New $980 Million Credit Facility
- Collegium Pharmaceutical closes $980M syndicated credit facility
- Dyne Therapeutics appoints Vikram Karnani to board of directors
- Collegium Pharmaceutical initiated with an Overweight at Barclays
- Collegium Pharmaceutical price target raised to $48 from $45 at Truist